Presentation is loading. Please wait.

Presentation is loading. Please wait.

Change over time in ossification of the posterior longitudinal ligament (OPLL)-like ectopic ossification in individual Enpp1ttw/ttw mice reported in figure.

Published bySusanti Tanuwidjaja Modified over 5 years ago

Similar presentations

Presentation on theme: "Change over time in ossification of the posterior longitudinal ligament (OPLL)-like ectopic ossification in individual Enpp1ttw/ttw mice reported in figure."— Presentation transcript:

1 Change over time in ossification of the posterior longitudinal ligament (OPLL)-like ectopic ossification in individual Enpp1ttw/ttw mice reported in figure 1. Change over time in ossification of the posterior longitudinal ligament (OPLL)-like ectopic ossification in individual Enpp1ttw/ttw mice reported in figure 1. Quantitation of OPLL-like ectopic ossification for each Enpp1ttw/ttw mouse either treated with famotidine from 4 weeks of age or controls. X-axes indicate ages of mice. Mineral cont., mineral content; Mineral dens., mineral density. Yujiro Maeda et al. RMD Open 2015;1:e000068 Copyright © BMJ Publishing Group & EULAR. All rights reserved.

Download ppt "Change over time in ossification of the posterior longitudinal ligament (OPLL)-like ectopic ossification in individual Enpp1ttw/ttw mice reported in figure."

Similar presentations

The genomic region spanning rs shows enhancer activity.

The genomic region spanning rs shows enhancer activity.
Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)

Persistence of first tumour necrosis factor alpha inhibitor (TNFi) by TNFi Kaplan-Meier plot of time (years) to discontinuation of treatment by TNFi. (A)
Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.

Flow chart of the steps in the EMEUNET Peer Review Mentoring Program.
Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.

Naïve B cells (CD19+CD27-), memory B cells (CD19+CD27+) and plasmablasts (PB CD27++) levels in patients with systemic sclerosis. Indicated points resemble.
Changes in evaluation indicators from baseline to 12 weeks per visit.

Changes in evaluation indicators from baseline to 12 weeks per visit.
Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.

Time to discontinuation of TNF-inhibitors (TNF-i) and non-TNF-inhibitors (non-TNFi), non-adjusted (non-adj) and adjusted (adj) for propensity score survival.
Percentage of patients achieving EULAR response

Percentage of patients achieving EULAR response
ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.

ASAS 20/40 response rates, and mean change from baseline in BASDAI through week 156* of treatment. *For patients who discontinued, the end of treatment.
The  core items were (A) hypoechogenicity, (B) heterogeneity (numerous anechoic areas), (C) hyperechoic bands, (D) calcifications (star), (E) lymph nodes.

The  core items were (A) hypoechogenicity, (B) heterogeneity (numerous anechoic areas), (C) hyperechoic bands, (D) calcifications (star), (E) lymph nodes.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
FTIR measurements from cortical and trabecular bone of rat tibia on day 22 post disease induction. FTIR measurements from cortical and trabecular bone.

FTIR measurements from cortical and trabecular bone of rat tibia on day 22 post disease induction. FTIR measurements from cortical and trabecular bone.
Baseline scores and corresponding changes to week 96 of the RAPID-axSpA trial for all CZP-treated patients included in the imaging substudy for: (A) SPARCC.

Baseline scores and corresponding changes to week 96 of the RAPID-axSpA trial for all CZP-treated patients included in the imaging substudy for: (A) SPARCC.
Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.

Flow diagram of the literature search process, including exclusions and reasons for exclusions. *Population of pregnant women (n=2), asymptomatic antiphospholipid.
VEGF is upregulated in the arterial wall of patients with biopsy-proven GCA but not in controls. VEGF is upregulated in the arterial wall of patients with.

VEGF is upregulated in the arterial wall of patients with biopsy-proven GCA but not in controls. VEGF is upregulated in the arterial wall of patients with.
Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.

Mean concentrations (mM) of PG1+2, PG3 and PG4+5 in patients with or without MTX-related toxicity at baseline, week 4 and week 24/26 in (A) CONCERTO and.
Radiological findings on the development of ossification of the posterior longitudinal ligament (OPLL)-like ectopic ossification in famotidine-treated.

Radiological findings on the development of ossification of the posterior longitudinal ligament (OPLL)-like ectopic ossification in famotidine-treated.
ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.

ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects at weeks 52, 104 and 156. ASAS 20/40 responses in anti-TNF-naïve and anti-TNF-IR subjects.
The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.

The patient profiles presented to rheumatologists in the discrete choice experiment (DCE). aCCP, anti-cyclic citrullinated peptide; DAS28, 28-joint Disease.
Frequency of patients in flare at each time point over 3 months

Frequency of patients in flare at each time point over 3 months
Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

Cumulative incidence of tuberculosis (TB) in certolizumab pegol (CZP)-treated patients with rheumatoid arthritis (RA) in the pooled RA safety database.

Similar presentations

Ads by Google